Pegargiminase
Diffuse Midline Glioma, H3 K27M-Mutant
Explore 10 assets in Diffuse Midline Glioma, H3 K27M-Mutant →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Sabine Mueller, MD, PhD
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07389278CT.gov Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Midline Glioma, H3 K27M-Mutant
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pegargiminase (this asset) | Sabine Mueller, MD, PhD | P1/2 | CC · 47 |
| Ribociclib | Nationwide Children's Hospital | P2 | B |
| Olutasidenib | Rigel Pharmaceuticals | P2 | CCC |
| Everolimus | Nationwide Children's Hospital | P2 | CCC |
| Nivestim | St. Jude Children's Research Hospital | P1 | CC |
| Trametinib | St. Jude Children's Research Hospital | P1 | CC |
| Sonidegib | St. Jude Children's Research Hospital | P1 | CC |
| Amxt1501 | Aminex Therapeutics, Inc. | P1/2 | CC |
| Dordaviprone | Jazz Pharmaceuticals | P2 | CC |
+6 more in the Diffuse Midline Glioma, H3 K27M-Mutant cohort
Other indications for Pegargiminase
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P3 | B · 60 |
| Cutaneous Melanoma | — | P2 | B · 56 |
| Neoplasm | — | P1/2 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pegargiminase in Diffuse Midline Glioma, H3 K27M-Mutant. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pegargiminase-diffuse-midline-glioma-h3-k27m-mutant
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →